Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cosmeceutical Pioneer Strivectin’s ‘Anti-Aging Solutions’ Draw Drug Claim Warning

This article was originally published in The Tan Sheet

Executive Summary

FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits.

You may also be interested in...



StriVectin Revises Ad With ‘Clear And Conspicuous’ Disclosure

The National Advertising Division, reflecting FTC enforcement in 2014 on inadequate disclosures, scrutinized print advertising for StriVectin Intensive Illuminating Serum. The skin care firm will revise the ad to address NAD’s concerns about the disclaimer’s placement, clarity and conspicuousness.

StriVectin Revises Ad With ‘Clear And Conspicuous’ Disclosure

The National Advertising Division, reflecting FTC enforcement in 2014 on inadequate disclosures, scrutinized print advertising for StriVectin Intensive Illuminating Serum. The skin care firm will revise the ad to address NAD’s concerns about the disclaimer’s placement, clarity and conspicuousness.

FDA Shows Skin Authority Who’s Boss In Warning For Drug Claims

Another skin care marketer, Skin Authority, receives an FDA warning letter for excessive product claims making its offerings drugs. The agency cites statements touting the firm’s ingredient benefits, including collagen production, improved circulation, inflammation relief and hyperpigmentation treatment, consistent with recent warnings issued to other cosmetics firms.

Related Content

Topics

UsernamePublicRestriction

Register

PS107568

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel